Axsome Therapeutics, Inc. has reported its first quarter 2025 financial results, showing significant growth in net product ...

Axsome Therapeutics reports 62% YoY revenue growth in Q1 2025, fueled by Auvelity & Sunosi. Key milestones include Symbravo launch & AXS-14 FDA decision.

Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...